<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: The identification of a neuroprotective drug for <z:hpo ids='HP_0001297'>stroke</z:hpo> remains elusive </plain></SENT>
<SENT sid="1" pm="."><plain>Given that mitochondria play a key role both in maintaining cellular energetic homeostasis and in triggering the activation of cell <z:hpo ids='HP_0011420'>death</z:hpo> pathways, we evaluated the efficacy of newly identified inhibitors of <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> release in <z:mp ids='MP_0005039'>hypoxia</z:mp>/<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> induced cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We demonstrate that methazolamide and <z:chebi fb="9" ids="16796">melatonin</z:chebi> are protective in cellular and in vivo models of neuronal <z:mp ids='MP_0005039'>hypoxia</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The effects of methazolamide and <z:chebi fb="9" ids="16796">melatonin</z:chebi> were tested in oxygen/<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation-induced <z:hpo ids='HP_0011420'>death</z:hpo> of primary cerebrocortical neurons </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001427'>Mitochondrial</z:hpo> membrane potential, release of apoptogenic <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> factors, pro-IL-1beta processing, and activation of caspase -1 and -3 were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>Methazolamide and <z:chebi fb="9" ids="16796">melatonin</z:chebi> were also studied in a middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> mouse model </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume, neurological function, and biochemical events were examined in the absence or presence of the 2 drugs </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Methazolamide and <z:chebi fb="9" ids="16796">melatonin</z:chebi> inhibit oxygen/<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation-induced cell <z:hpo ids='HP_0011420'>death</z:hpo>, loss of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential, release of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> factors, pro-IL-1beta processing, and activation of caspase-1 and -3 in primary cerebrocortical neurons </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, they decrease <z:mpath ids='MPATH_124'>infarct</z:mpath> size and improve neurological scores after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in mice </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: We demonstrate that methazolamide and <z:chebi fb="9" ids="16796">melatonin</z:chebi> are neuroprotective against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and provide evidence of the effectiveness of a <z:hpo ids='HP_0001427'>mitochondrial</z:hpo>-based drug screen in identifying neuroprotective drugs </plain></SENT>
<SENT sid="10" pm="."><plain>Given the proven human safety of <z:chebi fb="9" ids="16796">melatonin</z:chebi> and methazolamide, and their ability to cross the blood-brain-barrier, these drugs are attractive as potential novel therapies for ischemic injury </plain></SENT>
</text></document>